Cara Therapeutics Stock Price, News & Analysis (NASDAQ:CARA)

$12.05 -0.05 (-0.41 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$12.10
Today's Range$11.85 - $12.25
52-Week Range$8.61 - $28.50
Volume770,791 shs
Average Volume1.84 million shs
Market Capitalization$392.93 million
P/E RatioN/A
Dividend YieldN/A
Beta3.02

About Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics logoCara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:CARA
  • CUSIP: N/A
  • Web: www.caratherapeutics.com
Debt:
  • Current Ratio: 14.58%
  • Quick Ratio: 14.58%
Sales & Book Value:
  • Annual Sales: $90,000.00
  • Price / Sales: 4,366.12
  • Book Value: $1.86 per share
  • Price / Book: 6.48
Profitability:
  • Trailing EPS: ($2.29)
  • Net Income: $-57,280,000.00
  • Return on Equity: -91.47%
  • Return on Assets: -79.15%
Misc:
  • Employees: 34
  • Outstanding Shares: 32,610,000
 

Frequently Asked Questions for Cara Therapeutics (NASDAQ:CARA)

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) released its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.03. During the same period in the previous year, the business earned ($0.42) earnings per share. View Cara Therapeutics' Earnings History.

Where is Cara Therapeutics' stock going? Where will Cara Therapeutics' stock price be in 2017?

12 Wall Street analysts have issued 12 month price targets for Cara Therapeutics' stock. Their predictions range from $20.00 to $31.50. On average, they anticipate Cara Therapeutics' stock price to reach $26.19 in the next year. View Analyst Ratings for Cara Therapeutics.

What are Wall Street analysts saying about Cara Therapeutics stock?

Here are some recent quotes from research analysts about Cara Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (10/4/2017)
  • 2. Needham & Company LLC analysts commented, "Cara announced outcome of planned CR845 Phase 2/3 post-surgical pain trial interim power assessment today. We spoke w/ mgmt for an update. No changes will be made to current randomization ratio across the 3 arms (1:1:1 placebo, 0.5 ug/kg, 1.0ug/kg), however target enrollment will be increased from 125/ arm to 150/ arm. Other pre-specified options were ending trial early due to low probability of success or shifting enrollment to one optimal dose. We view outcome favorably, noting that the two dose arms were evaluated independently by Data Monitoring Cmtee. Implication is that both low and high dose CR845 have potential for statistically significant effect in view of DMC. We had been concerned that low and possibly high dose evaluated in this trial may not be sufficiently high for efficacy. Mgmt guided for completing enrollment for final analysis by YE17. Separately, top-line results from CR845 Phase 2b trial in Osteoarthritis are expected later this month. We are favorably inclined based on encouraging trends in an 80-pt 2wk Phase 2a trial, but acknowledge risks tied to absence of placebo arm." (6/21/2017)
  • 3. HC Wainwright analysts commented, "CR845 as safe as placebo in respiratory safety Phase 1. Cara announced positive data this morning from a 15-patient Phase 1 trial in healthy volunteers designed to formally test for IV ‘845’s impact on respiratory drive, as respiratory depression remains one of the more severe, and potentially life-threatening, side effects of mu opioids, which ‘845 is not. The trial was a three-way crossover design utilizing the expected therapeutic dose of 1.0 ug/kg, as well as a 5.0 ug/kg supratherapeutic dose to test the upper bounds for safety. Patient respiratory drive was measured via end-tidal CO2 (ETCO2), oxygen saturation (SpO2), and respiratory rate, with primary endpoints focused on the former two. ETCO2 ranged from 36.1 to 37.8 mmHg prior to dosing, and remained well below the endpoint threshold of a 10mmHg sustained increase in ETCO2, with values of 38.1, 38.1, and 38.3 mmHg for the placebo, 1.0 ug/kg, and 5.0 ug/kg doses, respectively, one hour after administration. Both doses of ‘845 also hit on the SpO2 primary endpoint (needed to show SpO2 which did not consistently fall below 92%), with pre-treatment levels ranging from 98.3% to 98.9%, finishing an hour later at 97.8%, 98.2%, and 97.9% for the placebo,1.0 ug/kg, and 5.0 ug/kg doses, respectively. While these two primary endpoints only measured through an hour after treatment, no significant differences were seen on all three measures of respiratory drive throughout the entire 4-hour observation period of the study." (4/24/2017)
  • 4. Cantor Fitzgerald analysts commented, "The Phase 1 safety trial of IV CR845 showed no significant differences in respiratory drive vs. placebo at super-therapeutic dosing levels." (4/24/2017)
  • 5. Piper Jaffray Companies analysts commented, "Today Cara reported positive results from Part A of its Phase II/III trial for IV CR845 in uremic pruritus (UP). In our view, these results are compelling in terms of impact on worst itching scores together with more global measures of quality of life within the context of an 8-week study, as well as safety/tolerability at the go-forward doses of 0.5mcg/kg and 1.0mcg/kg. We see the robust efficacy vs safety data from this Phase II as reducing clinical risk for a broader pivotal program planned to begin by YE17. And beyond the Phase III program, we see this dataset as potentially reducing regulatory and commercial risk, and enhancing value of this asset, in the longer-term. In advance of further clinical progress in UP, including an EOP2 and Phase III start yet in '17, as well as chronic pain and post-op pain updates during 2Q17, we reiterate OW on Cara." (3/28/2017)

Who are some of Cara Therapeutics' key competitors?

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the folowing people:

  • Derek T. Chalmers Ph.D., President, Chief Executive Officer, Director (Age 53)
  • Mani Mohindru Ph.D., Chief Financial Officer, Chief Strategy Officer (Age 45)
  • Michael E. Lewis, Chief Scientific Officer (Age 65)
  • Frederique Menzaghi Ph.D, Vice President, Research & Development (Age 50)
  • Joseph William Stauffer, Chief Medical Officer (Age 50)
  • Harrison M. Bains Jr., Independent Director (Age 73)
  • Jeffrey L. Ives Ph.D., Independent Director (Age 66)
  • Dean Slagel, Independent Director (Age 47)
  • Martin A. Vogelbaum, Independent Director (Age 53)

Who owns Cara Therapeutics stock?

Cara Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Disciplined Growth Investors Inc. MN (2.60%), JPMorgan Chase & Co. (1.10%), C WorldWide Group Holding A S (0.89%), California Public Employees Retirement System (0.51%), Bank of New York Mellon Corp (0.37%) and Stifel Financial Corp (0.20%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi, Michael E Lewis and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics.

Who sold Cara Therapeutics stock? Who is selling Cara Therapeutics stock?

Cara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Bank of New York Mellon Corp, Stifel Financial Corp, Disciplined Growth Investors Inc. MN, Jane Street Group LLC and California State Teachers Retirement System. Company insiders that have sold Cara Therapeutics company stock in the last year include Dean Slagel, Derek T Chalmers and Frederique PhD Menzaghi. View Insider Buying and Selling for Cara Therapeutics.

Who bought Cara Therapeutics stock? Who is buying Cara Therapeutics stock?

Cara Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, JPMorgan Chase & Co., Dynamic Technology Lab Private Ltd, SG Americas Securities LLC, California Public Employees Retirement System, State Board of Administration of Florida Retirement System, Commonwealth Equity Services Inc and TD Asset Management Inc.. View Insider Buying and Selling for Cara Therapeutics.

How do I buy Cara Therapeutics stock?

Shares of Cara Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cara Therapeutics' stock price today?

One share of Cara Therapeutics stock can currently be purchased for approximately $12.05.

How big of a company is Cara Therapeutics?

Cara Therapeutics has a market capitalization of $392.93 million and generates $90,000.00 in revenue each year. The biopharmaceutical company earns $-57,280,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Cara Therapeutics employs 34 workers across the globe.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 4 Stamford Plz, STAMFORD, CT 06902-3834, United States. The biopharmaceutical company can be reached via phone at +1-203-4063700.


MarketBeat Community Rating for Cara Therapeutics (NASDAQ CARA)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  381 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  538
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Cara Therapeutics (NASDAQ:CARA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 3 Hold Ratings, 9 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $26.19 (117.36% upside)

Consensus Price Target History for Cara Therapeutics (NASDAQ:CARA)

Price Target History for Cara Therapeutics (NASDAQ:CARA)

Analysts' Ratings History for Cara Therapeutics (NASDAQ:CARA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017Canaccord GenuitySet Price TargetBuy$25.00N/AView Rating Details
11/7/2017Raymond James Financial, Inc.Boost Price TargetMarket Perform$25.00 -> $26.00N/AView Rating Details
11/7/2017CIBCLower Price Target$26.00 -> $24.00N/AView Rating Details
11/7/2017BMO Capital MarketsReiterated RatingMarket Perform$25.00N/AView Rating Details
10/17/2017ScotiabankBoost Price TargetOutperform$31.00 -> $31.50N/AView Rating Details
10/4/2017Needham & Company LLCReiterated RatingBuy$23.00LowView Rating Details
8/5/2017Piper Jaffray CompaniesSet Price TargetBuy$27.00HighView Rating Details
8/4/2017HC WainwrightReiterated RatingBuy$30.00HighView Rating Details
8/3/2017Royal Bank Of CanadaLower Price TargetOutperform$31.00 -> $29.00LowView Rating Details
6/30/2017LaidlawLower Price TargetBuy$35.00 -> $30.00HighView Rating Details
6/30/2017Stifel NicolausReiterated RatingBuy -> Buy$24.00 -> $20.00HighView Rating Details
6/30/2017Janney Montgomery ScottDowngradeBuy -> Neutral$22.00 -> $21.00HighView Rating Details
5/19/2017Cantor FitzgeraldReiterated RatingOverweight$29.00LowView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Cara Therapeutics (NASDAQ:CARA)

Earnings by Quarter for Cara Therapeutics (NASDAQ:CARA)

Earnings History by Quarter for Cara Therapeutics (NASDAQ CARA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.35)($0.38)$0.27 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.61)($0.29)$0.13 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.73)($0.81)$0.11 million$0.91 millionViewListenView Earnings Details
11/3/2016Q3($0.47)($0.42)$0.09 millionViewN/AView Earnings Details
8/4/2016Q216($0.42)($0.48)$0.13 million$0.08 millionViewN/AView Earnings Details
5/5/2016Q116($0.40)($0.39)$0.03 million$0.01 millionViewN/AView Earnings Details
3/10/2016Q4($0.33)($0.35)$0.53 millionViewListenView Earnings Details
11/9/2015Q315($0.27)($0.19)$1.86 million$2.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.24)($0.25)$0.50 million$0.87 millionViewListenView Earnings Details
5/12/2015Q415($0.22)($0.21)$0.70 million$0.50 millionViewListenView Earnings Details
3/26/2015Q4($0.28)($0.18)$1.00 million$0.91 millionViewListenView Earnings Details
11/10/2014Q314($0.22)($0.29)$0.13 million$1.13 millionViewN/AView Earnings Details
8/7/2014Q2($0.27)($0.16)$0.08 million$0.96 millionViewN/AView Earnings Details
5/12/2014Q1($0.14)($0.22)$0.30 million$0.18 millionViewN/AView Earnings Details
3/27/2014($0.18)($0.49)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cara Therapeutics (NASDAQ:CARA)
Current Year EPS Consensus Estimate: $-1.84 EPS
Next Year EPS Consensus Estimate: $-1.77 EPS

Dividends

Dividend History for Cara Therapeutics (NASDAQ:CARA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cara Therapeutics (NASDAQ CARA)

Insider Ownership Percentage: 7.50%
Institutional Ownership Percentage: 58.74%
Insider Trades by Quarter for Cara Therapeutics (NASDAQ:CARA)
Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Insider Trades by Quarter for Cara Therapeutics (NASDAQ CARA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2017Derek T ChalmersCEOSell16,000$12.66$202,560.00View SEC Filing  
7/14/2017Derek T ChalmersCEOSell25,000$15.05$376,250.00View SEC Filing  
7/14/2017Frederique Ph.D. MenzaghiVPSell3,000$15.00$45,000.00View SEC Filing  
6/29/2017Dean SlagelDirectorSell250,000$25.87$6,467,500.00View SEC Filing  
3/31/2017Ventures Vi Lp RhoMajor ShareholderBuy500,000$18.19$9,095,000.00View SEC Filing  
4/20/2016Frederique Ph.D. MenzaghiVPSell6,000$9.00$54,000.00View SEC Filing  
3/17/2016Ventures Vi Lp RhoMajor ShareholderBuy400,000$4.87$1,948,000.00View SEC Filing  
2/3/2016Frederique Ph.D. MenzaghiVPSell6,000$9.04$54,240.00View SEC Filing  
1/26/2016Michael E LewisInsiderSell7,262$10.93$79,373.66View SEC Filing  
1/6/2016Derek T ChalmersCEOSell12,500$17.22$215,250.00View SEC Filing  
12/1/2015Frederique Ph.D. MenzaghiVPSell6,000$16.21$97,260.00View SEC Filing  
11/2/2015Frederique Ph.D. MenzaghiVPSell6,000$14.26$85,560.00View SEC Filing  
10/1/2015Frederique Ph.D. MenzaghiVPSell6,000$13.95$83,700.00View SEC Filing  
9/1/2015Frederique Ph.D. MenzaghiVPSell7,000$18.63$130,410.00View SEC Filing  
8/18/2015Josef SchoellCFOBuy3,000$22.10$66,300.00View SEC Filing  
6/1/2015Michael E LewisInsiderSell7,262$9.50$68,989.00View SEC Filing  
5/19/2015Dean SlagelDirectorSell188,811$10.02$1,891,886.22View SEC Filing  
4/1/2015Michael E LewisInsiderSell7,262$9.90$71,893.80View SEC Filing  
3/2/2015Michael E LewisInsiderSell7,262$10.11$73,418.82View SEC Filing  
2/2/2015Michael E LewisInsiderSell7,262$10.60$76,977.20View SEC Filing  
2/5/2014Ventures Vi Lp RhoMajor ShareholderBuy225,818$11.00$2,483,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cara Therapeutics (NASDAQ CARA)

Source:
DateHeadline
Cara Therapeutics, Inc. (CARA) Given a $25.00 Price Target by Canaccord Genuity AnalystsCara Therapeutics, Inc. (CARA) Given a $25.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - November 21 at 8:14 PM
Cara Therapeutics, Inc. (CARA) Receives Average Recommendation of "Buy" from AnalystsCara Therapeutics, Inc. (CARA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 20 at 6:04 AM
Cara Therapeutics (CARA) Presents At Jefferies 2017 London Healthcare Conference - SlideshowCara Therapeutics (CARA) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 2:32 PM
CARA Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CARA-US : November 13, 2017CARA Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CARA-US : November 13, 2017
finance.yahoo.com - November 13 at 11:33 PM
Head-To-Head Survey: Exact Sciences Corporation (EXAS) versus Cara Therapeutics (CARA)Head-To-Head Survey: Exact Sciences Corporation (EXAS) versus Cara Therapeutics (CARA)
www.americanbankingnews.com - November 10 at 5:24 AM
Technical Insights on Biotech Stocks -- Cara Therapeutics, Catabasis Pharma, Cerus, and Genocea BiosciencesTechnical Insights on Biotech Stocks -- Cara Therapeutics, Catabasis Pharma, Cerus, and Genocea Biosciences
finance.yahoo.com - November 6 at 6:05 PM
Derek T. Chalmers Sells 16,000 Shares of Cara Therapeutics, Inc. (CARA) StockDerek T. Chalmers Sells 16,000 Shares of Cara Therapeutics, Inc. (CARA) Stock
www.americanbankingnews.com - November 3 at 8:58 PM
Cara Therapeutics, Inc. (CARA) Announces Quarterly  Earnings ResultsCara Therapeutics, Inc. (CARA) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 3 at 5:48 PM
Cara Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Cara Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 3 at 8:06 AM
Edited Transcript of CARA earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of CARA earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 3 at 8:06 AM
Data Shows Sales of Legal Cannabis Products Remain StrongData Shows Sales of Legal Cannabis Products Remain Strong
www.prnewswire.com - November 2 at 5:41 PM
BRIEF-Cara Therapeutics Inc reports Q3 loss per share $0.38BRIEF-Cara Therapeutics Inc reports Q3 loss per share $0.38
www.reuters.com - November 2 at 5:41 PM
Cara Therapeutics Inc to Host Earnings CallCara Therapeutics Inc to Host Earnings Call
finance.yahoo.com - November 2 at 5:41 PM
Cara reports 3Q lossCara reports 3Q loss
finance.yahoo.com - November 2 at 5:40 PM
Cara Therapeutics (CARA) to Present Late-Breaking Data at ACR/ARHPCara Therapeutics (CARA) to Present Late-Breaking Data at ACR/ARHP
www.streetinsider.com - November 1 at 4:12 AM
Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting - GlobeNewswire (press release)Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting - GlobeNewswire (press release)
globenewswire.com - October 31 at 6:08 PM
Enteris BioPharmas "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence™-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease PatientsEnteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence™-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients
finance.yahoo.com - October 31 at 6:08 PM
Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual MeetingCara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting
finance.yahoo.com - October 31 at 6:07 PM
3 Small-Cap Marijuana Stocks to Get on Your Radar3 Small-Cap Marijuana Stocks to Get on Your Radar
finance.yahoo.com - October 27 at 7:30 PM
Cara Therapeutics to Announce Third Quarter 2017 Financial Results on November 2, 2017 - GlobeNewswire (press release)Cara Therapeutics to Announce Third Quarter 2017 Financial Results on November 2, 2017 - GlobeNewswire (press release)
globenewswire.com - October 26 at 5:09 PM
Cara Therapeutics to Announce Third Quarter 2017 Financial Results on November 2, 2017Cara Therapeutics to Announce Third Quarter 2017 Financial Results on November 2, 2017
finance.yahoo.com - October 26 at 5:09 PM
Cara Therapeutics, Inc. (CARA) Receives Average Rating of "Buy" from AnalystsCara Therapeutics, Inc. (CARA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 26 at 5:54 AM
Cara Therapeutics (CARA) Reports Dosing of First Patient in Phase 1 Study of Oral CR845Cara Therapeutics (CARA) Reports Dosing of First Patient in Phase 1 Study of Oral CR845
www.streetinsider.com - October 25 at 11:28 PM
Cara Therapeutics Doses First Patient in Phase 1 Study of Oral CR845 in Non-Hemodialysis Chronic Kidney Disease PatientsCara Therapeutics Doses First Patient in Phase 1 Study of Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients
finance.yahoo.com - October 25 at 6:26 PM
Cara Therapeutics Scratching A Big Niche - Seeking AlphaCara Therapeutics Scratching A Big Niche - Seeking Alpha
seekingalpha.com - October 25 at 5:17 AM
3 Reasons Cara Therapeutics Is a Better Growth Stock Than Novavax - Motley Fool3 Reasons Cara Therapeutics Is a Better Growth Stock Than Novavax - Motley Fool
www.fool.com - October 20 at 3:45 AM
3 Reasons Cara Therapeutics Is a Better Growth Stock Than Novavax3 Reasons Cara Therapeutics Is a Better Growth Stock Than Novavax
finance.yahoo.com - October 19 at 5:28 PM
Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for IV CR845 in Chronic Kidney Disease ... - GlobeNewswire (press release)Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for IV CR845 in Chronic Kidney Disease ... - GlobeNewswire (press release)
globenewswire.com - October 17 at 10:43 PM
Contrasting Cara Therapeutics (CARA) & Its CompetitorsContrasting Cara Therapeutics (CARA) & Its Competitors
www.americanbankingnews.com - October 17 at 8:28 PM
Cara Therapeutics Announces Participation in ANESTHESIOLOGY® 2017Cara Therapeutics Announces Participation in ANESTHESIOLOGY® 2017
finance.yahoo.com - October 17 at 5:42 PM
Cara Therapeutics, Inc. (CARA) PT Raised to $31.50Cara Therapeutics, Inc. (CARA) PT Raised to $31.50
www.americanbankingnews.com - October 17 at 2:20 PM
Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated PruritusCara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
finance.yahoo.com - October 16 at 5:36 PM
Cara Therapeutics to Present Data at Kidney Week 2017Cara Therapeutics to Present Data at Kidney Week 2017
finance.yahoo.com - October 16 at 5:36 PM
Where Will Cara Therapeutics Be in 5 Years?Where Will Cara Therapeutics Be in 5 Years?
finance.yahoo.com - October 14 at 3:38 AM
Commit To Purchase Cara Therapeutics At $10, Earn 25.1% Annualized Using Options - TheStreet.comCommit To Purchase Cara Therapeutics At $10, Earn 25.1% Annualized Using Options - TheStreet.com
www.thestreet.com - October 12 at 5:46 PM
Where Will Cara Therapeutics Be in 5 Years? - Motley FoolWhere Will Cara Therapeutics Be in 5 Years? - Motley Fool
www.fool.com - October 6 at 5:09 PM
Cara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain ConferenceCara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference
finance.yahoo.com - October 5 at 11:53 AM
CARA Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CARA-US : October 3, 2017CARA Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CARA-US : October 3, 2017
finance.yahoo.com - October 3 at 4:51 PM
Cara Therapeutics, Inc. (CARA) Receives Consensus Recommendation of "Buy" from AnalystsCara Therapeutics, Inc. (CARA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 1 at 4:44 AM
Cara Therapeutics, Inc. (CARA) PT Lowered to $31.00 at ScotiabankCara Therapeutics, Inc. (CARA) PT Lowered to $31.00 at Scotiabank
www.americanbankingnews.com - September 28 at 2:28 PM
CARA Therapeutics, Inc. – Value Analysis (NASDAQ:CARA) : September 12, 2017CARA Therapeutics, Inc. – Value Analysis (NASDAQ:CARA) : September 12, 2017
finance.yahoo.com - September 12 at 10:36 PM
Heres Why the Best Is Yet to Come for Cara Therapeutics, Inc. - Motley FoolHere's Why the Best Is Yet to Come for Cara Therapeutics, Inc. - Motley Fool
www.fool.com - September 11 at 5:33 PM
CARA Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CARA-US : September 11, 2017CARA Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CARA-US : September 11, 2017
finance.yahoo.com - September 11 at 5:33 PM
Here's Why the Best Is Yet to Come for Cara Therapeutics, Inc.Here's Why the Best Is Yet to Come for Cara Therapeutics, Inc.
finance.yahoo.com - September 10 at 4:28 PM
Heres Why the Best Is Yet to Come for Cara Therapeutics, Inc.Here's Why the Best Is Yet to Come for Cara Therapeutics, Inc.
www.fool.com - September 10 at 10:10 AM
Heres Why Cara Therapeutics Rose 9.6% in August - Motley FoolHere's Why Cara Therapeutics Rose 9.6% in August - Motley Fool
www.fool.com - September 8 at 5:19 PM
Stocks With Rising Relative Price Strength: Cara TherapeuticsStocks With Rising Relative Price Strength: Cara Therapeutics
finance.yahoo.com - September 8 at 5:19 PM
Here's Why Cara Therapeutics Rose 9.6% in AugustHere's Why Cara Therapeutics Rose 9.6% in August
finance.yahoo.com - September 7 at 4:39 PM
Upcoming Data Releases Fueled Strong Gains in These 2 Marijuana Stocks Last WeekUpcoming Data Releases Fueled Strong Gains in These 2 Marijuana Stocks Last Week
finance.yahoo.com - September 6 at 4:58 PM
Upcoming Data Releases Fueled Strong Gains in These 2 Marijuana Stocks Last WeekUpcoming Data Releases Fueled Strong Gains in These 2 Marijuana Stocks Last Week
finance.yahoo.com - September 6 at 4:58 PM

Social Media

Financials

Chart

Cara Therapeutics (NASDAQ CARA) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.